Health2Sync and Novo Nordisk Pharma Korea, Ltd. Launch Smart Cap Mallya® for FlexTouch® Insulin Pens Integration in South Korea, Enhancing insulin administration via Digital Diabetes Care
This innovation comes at a critical moment. Managing insulin administration records is a challenging task for both diabetes patients and healthcare professionals. In fact, a multinational survey of diabetes patients receiving insulin treatment and physicians treating diabetes patients found that 27.6% of patients experience difficulty administering insulin at the prescribed time or with meals. In the same study, 54.5% of physicians reported that their patients experience difficulty administering insulin at the prescribed time or with meals.
Mallya®, when paired with Health2Sync's connected ecosystem, significantly lowers this burden. Patients using FlexTouch® insulin pens can now have their dosage, time, and frequency data recorded and visualized in real time within the SugarGenie app.
'This integration is connecting yet another integral part in digital diabetes care,' said Ed Deng, CEO and Co-founder of Health2Sync. 'By connecting the data of Mallya® to SugarGenie, we're improving accuracy in insulin tracking and expanding the depth of data available to patients and care teams. Our platform enables insulin logs to be viewed alongside blood glucose, meals, and physical activity, offering a full circle understanding of each patient's health context.'
Deng continued: 'For healthcare professionals, this means faster, smarter decisions. Our care provider portal lets clinicians view real-time patient data We're turning disconnected data points into a unified, actionable picture of care, without placing additional burden on patients.'
SugarGenie's integration with Mallya® supports remote care models and automated record-keeping—an increasingly critical combination for long-term chronic condition management in South Korea. With its clean interface, real-time sync, and care team dashboard, SugarGenie is a key digital infrastructure in Korea's diabetes treatment landscape.
'Digital healthcare has become a key tool in enhancing the efficiency and convenience of diabetes treatment,' said Kasper Roseeuw Poulsen, General Manager of Novo Nordisk Pharma Korea, Ltd.. 'For over a century, Novo Nordisk has supported patients through holistic solutions, and our collaboration with Health2Sync is also a continuation of that commitment. We hope this strategic collaboration will help create a more systematic and efficient treatment environment for both patients and healthcare professionals in Korea.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
a day ago
- Malaysian Reserve
OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology
BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ — OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ('Term Sheet') with Woori IO Co., Ltd. ('WORIO'), a South Korean medical device company developing next-generation noninvasive glucose monitoring technology. The agreement sets forth certain key terms for a strategic acquisition of WORIO by OSR Holdings' Korean affiliate, OSR Holdings Co., Ltd. ('OSRK'). Under the proposed structure, WORIO will become a wholly owned subsidiary of OSRK. Shareholders of WORIO will receive newly issued shares of OSRK through the share exchange and may be eligible to convert them into OSRH common stock traded on NASDAQ, subject to certain conditions including '$10 per OSRH share' WORIO shareholders may convert their OSRK shares into OSRH shares at a fixed exchange ratio of 1 OSRK share = 12.96 OSRH shares, provided that OSRH's stock price reaches $10.00 at least once within three years following the signing of the Term Sheet. If this condition is not met, the parties have agreed to renegotiate in good faith. The agreement includes a 6-month exclusivity period, during which OSRK will conduct confirmatory legal and financial due diligence with a target to complete this transaction within this exclusivity proprietary platform uses near-infrared spectroscopy (NIRS) to measure glucose without needles, sensors, or skin penetration — representing a truly noninvasive alternative to today's continuous glucose monitors (CGMs). Its solution aims to eliminate the burden of pain and daily finger pricks for millions of people with diabetes. According to recent global market research, the blood glucose monitoring devices market is expected to exceed $40 billion by 2030, growing at a CAGR of 8–10%, driven by rising diabetes prevalence and the convergence of medical technology with consumer electronics. Demand for noninvasive and wearable monitoring systems is expected to be a major growth driver. Dexcom, one of the market leaders in minimally invasive CGM which is the current standard of care has more than $32 billion in market capitalization (as of July 11), underscoring the significant commercial potential of advanced glucose monitoring solutions. Noninvasive alternatives hold tremendous promise and are poised to become an integral part of diabetes management in the future. WORIO has completed a proof-of-concept study with the Korea University Hospital (Guro) to validate the accuracy and effectiveness of its prototype devices and the data measured by them, based on which the company plans to enter a larger confirmatory trial to be registered with the Ministry of Food and Drug Safety (MFDS) of Korea for medical device approval pathway. WORIO's noninvasive technology is well positioned to be integrated into wearable glucose monitoring devices such as smart watches — WORIO has been selected by Samsung Electronics' innovative startup program ('C-Lab Outside') in Q1 2025.'We believe this initial milestone with Woori IO aligns strongly with our mission to accelerate breakthrough healthcare innovations with global impact,' said Peter Hwang, CEO of OSRH. 'Woori IO's breakthrough noninvasive glucose monitoring platform, coupled with its high-profile partnership with global companies, puts OSRH in a position to become a first mover in this fast-growing global market.'Following the signing of this Term Sheet, both parties will proceed with due diligence and aim to execute definitive agreements within the 6 months exclusivity period. About OSR Holdings, Inc. OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development. For more information, visit About Woori IO Co., Ltd. Woori IO is a medical device company based in Jeonju, South Korea, focused on the development of noninvasive biosensing solutions. Its proprietary NIRS-based glucose monitoring system enables accurate, pain-free, and user-friendly diabetes management, with strong potential for wearable integration. For more information, visit Contact:Investor RelationsOSR Holdings, IR@ Website:
Malaysian Reserve
2 days ago
- Malaysian Reserve
British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)
TORONTO, July 23, 2025 /CNW/ – Elvium Life Sciences is pleased to announce the addition of FOQUEST® (methylphenidate hydrochloride controlled release capsules) to the British Columbia1 PharmaCare formulary and First Nations Health Authority (FNHA) Pharmacy Benefit. With provincial funding in place in British Columbia, FOQUEST® is now reimbursed from coast to coast on all provincial drug plans across Canada. 'Public funding in British Columbia ensures equitable access to ADHD treatments in BC,' said Juanita Beaudry, Executive Director of the Centre for ADHD Awareness (CADDAC) 'This latest approval now provides access across Canada to another treatment option for patients.' British Columbia now joins Alberta2, Saskatchewan3, Manitoba4, Ontario5, Quebec6, Atlantic Canada7,8,9,10, the Non-Insured Health Benefit Plan11 and Correctional Service Canada in providing public formulary coverage for FOQUEST® for the treatment of ADHD in patients aged six years and older. 'Elvium Life Sciences is very pleased that British Columbia has now included Foquest on the BC PharmaCare Formulary to give physicians an additional choice for their ADHD patients who require public coverage,' said Jodan Ratz, Country Medical Director at Elvium Life Sciences. 'We thank the province for its decision which now means that all ADHD patients aged six years of age and older have equivalent access to Foquest should this be the right treatment for them.' See the full Canadian Product Monograph for FOQUEST®12 The Product Monograph for FOQUEST® contains a Serious Warning and Precaution for drug dependence, emphasizing that abuse of FOQUEST® can lead to dependence. Healthcare professionals should assess the risk of abuse prior to prescribing FOQUEST®, including in patients with a history of drug dependence or alcoholism, and monitor for signs of abuse and dependence while patients are on therapy. FOQUEST® is a once-daily, long-acting methylphenidate controlled-release capsule for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients greater than or equal to six years of age. The maximum daily dose of FOQUEST® for children and adolescents (6 to <18 years old) is 70mg, and the maximum daily dose for adults (≥18 years old) is 100 mg. Adverse events observed with FOQUEST® treatment mainly reflect side effects commonly associated with methylphenidate use. Very common adverse events reported by patients treated with FOQUEST® were headache, insomnia, decreased appetite and abdominal pain. Most of the events were mild to moderate in severity. About Elvium Life Sciences Elvium Life Sciences is an independent associated company of Purdue Pharma (Canada), that focuses on specialty pharmaceutical products committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) and products for ophthalmology. For more information, please visit FOQUEST® is a registered trademark of Purdue Pharma and is used under licence. References: 1. Available at: Accessed July 23, 2025 2. Available at: Accessed July 18, 2025 3. Available at: Accessed July 18, 2025 4. Available at: Accessed July 18, 2025 5. Available at: Accessed July 18, 2025 6. Available at: Accessed July 18, 2025 7. Available at: Accessed July 18, 2025 8. Available at: Accessed July 18, 2025 9. Available at: Accessed July 18, 2025 10. Available at: Accessed July 18, 2025 11. Available at: Accessed July 18, 2025. 12. Available at:
Malaysian Reserve
2 days ago
- Malaysian Reserve
NAPA Anesthesia Honored with RPI Best Practice Standards® Award for Excellence in Employee Recognition
SUNRISE, Fla., July 23, 2025 /PRNewswire/ — North American Partners in Anesthesia (NAPA), the nation's largest single-specialty anesthesia services organization, has been awarded a 2025 Best Practice Standards® Award by Recognition Professionals International (RPI). NAPA was honored for NAPApplause, which fosters a culture where employees feel valued for their contributions and connected to NAPA's mission to be the "Destination of Choice for All." NAPA joins American Airlines, Banfield Pet Hospital, General Dynamics Information Technology, and Liberty Mutual Insurance in receiving awards for recognition excellence through programs aligned with RPI's seven Best Practice Standards®. "We believe a comprehensive recognition approach that integrates formal and informal appreciation is essential to our success," said Ian Kearney, Vice President of People & Organization at NAPA. "This includes peer-to-peer feedback, milestone recognition, performance awards, and wellness-based incentives." NAPApplause celebrates the meaningful contributions of NAPA team members, from major milestones to everyday moments that make a difference. "When people feel seen and appreciated, they are more motivated to bring their best every day," said Jill Duca, Senior Manager of Organizational Effectiveness at NAPA. To date, NAPA employees have submitted more than 250 formal award nominations through NAPApplause, and within weeks of launching a new peer feedback feature in 2025, nearly 100 appreciation messages were shared between colleagues. The RPI Best Practice Standards® are based on academic research and real-world implementation across organizations of all sizes. Each standard offers a framework for designing recognition programs that promote employee engagement, enhance culture, and drive business outcomes. About North American Partners in Anesthesia As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day. NAPA has grown to become the nation's single-specialty leader in anesthesia. Our nearly 5,000 clinicians serve more than 2 million patients annually at nearly 400 healthcare facilities in 23 states. For more information, please visit About Recognition Professionals International Recognition Professionals International (RPI) is a Strategic Industry Group (SIG) within the Incentive Marketing Association. RPI is the only professional association at the forefront of workforce recognition through its sole focus on recognition innovations and education as a systematic method for improvements in the workplace. RPI members are recognition experts who practice the art of recognition at their companies and recognition solution providers who provide recognition services, tools and platforms to companies as a service (including consultation, program design and technology).
